Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.9 USD | -0.07% | -9.74% | -36.18% |
May. 09 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
May. 09 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
Financials (USD)
Sales 2024 * | 235K | Sales 2025 * | 330K | Capitalization | 887M |
---|---|---|---|---|---|
Net income 2024 * | -226M | Net income 2025 * | -266M | EV / Sales 2024 * | 1,811 x |
Net cash position 2024 * | 462M | Net cash position 2025 * | 625M | EV / Sales 2025 * | 794 x |
P/E ratio 2024 * |
-3.8
x | P/E ratio 2025 * |
-3.54
x | Employees | 94 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.69% |
Latest transcript on Viridian Therapeutics, Inc.
1 day | -0.07% | ||
1 week | -9.74% | ||
Current month | +4.83% | ||
1 month | -12.52% | ||
3 months | -29.37% | ||
6 months | +1.02% | ||
Current year | -36.18% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 23-10-29 |
Seth Harmon
DFI | Director of Finance/CFO | 45 | 23-04-30 |
Thomas Ciulla
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 18-01-02 |
Tomas Kiselak
CHM | Chairman | 38 | 20-10-27 |
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 23-10-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.06% | 0 M€ | +2.72% | - | |
0.02% | 2 M€ | -.--% | ||
0.01% | 0 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 13.9 | -0.07% | 858,169 |
24-05-09 | 13.91 | -6.64% | 1,729,832 |
24-05-08 | 14.9 | -1.59% | 1,013,672 |
24-05-07 | 15.14 | -2.89% | 643,741 |
24-05-06 | 15.59 | +1.23% | 568,997 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.18% | 887M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- VRDN Stock